# Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma

> **NCT00720876** · PHASE2 · COMPLETED · sponsor: **City of Hope Medical Center** · enrollment: 30 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **BIOLOGICAL:** rituximab
- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00720876
- **Lead sponsor:** City of Hope Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07-23
- **Primary completion:** 2017-06-08
- **Final completion:** 2017-06-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-08-07

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00720876

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00720876, "Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00720876. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*